Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bespoke ExtractsBSPK 3-Year EBITDA Growth Rate is 20.30% as of Sep. 2025, which is 25% above its 10-year median of 16.20. The stock has 3 warning signs investors should review. Among 809 Drug Manufacturers companies, Bespoke Extracts ranks better than 68.48% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 20.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Bespoke Extracts was 73.60% per year. The lowest was -24.70% per year. And the median was 16.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Bespoke Extracts 3-Year EBITDA Growth Rate Related Terms
BSPK vs ZTS, UTHR, VTRS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bespoke Extracts's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bespoke Extracts 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bespoke Extracts's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Bespoke Extracts's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 20.30% mean?
Bespoke Extracts (BSPK) has a 3-Year EBITDA Growth Rate of 20.30% as of Sep. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Bespoke Extracts and its competitors. This is 25% above median its historical median of 16.20. According to the industry distribution chart, Bespoke Extracts ranks #255 out of 809 companies in the Drug Manufacturers industry, placing it in the top 31.5%.
Is Bespoke Extracts' 3-Year EBITDA Growth Rate too high?
Bespoke Extracts' current 3-Year EBITDA Growth Rate of 20.30% is 25% above median its 10-year median of 16.20. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. Bespoke Extracts' value of 20.30% is 130.7% above this industry median. Based on the distribution chart, Bespoke Extracts ranks #255 out of 809 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Bespoke Extracts' 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bespoke Extracts ranks #255 out of 809 companies for 3-Year EBITDA Growth Rate. This puts Bespoke Extracts in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.80. Bespoke Extracts' value of 20.30% is 130.7% above this benchmark. While the company's 10-year median is 16.20 vs. the industry median of 8.80, Bespoke Extracts has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bespoke Extracts's current 3-Year EBITDA Growth Rate of 20.30% is 130.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Bespoke Extracts and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bespoke Extracts's current 3-Year EBITDA Growth Rate is 20.30%, which is 25% above median its own 10-year median of 16.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bespoke Extracts stock overvalued right now?
Bespoke Extracts (BSPK) has a current 3-Year EBITDA Growth Rate of 20.30%. The current 3-Year EBITDA Growth Rate is 20.30%, which is 25% above median its 10-year median of 16.20 and 130.7% above the Drug Manufacturers industry median of 8.80. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Bespoke Extracts (BSPK), the current 3-Year EBITDA Growth Rate is 20.30% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bespoke Extracts Inc is focused on selling its proprietary line of specially-formulated, quality, hemp-derived CBD products. The company owns, manufactures, and distributes a portfolio of cannabis consumer packaged goods brands including Fresh Joints, Doobskis, DutchBlunts, and Wee Joints, to licensed marijuana dispensaries across Colorado.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSPK has been successfully added to your 
